Fox Run Management, L.L.C. Fate Therapeutics Inc Transaction History

Fox Run Management, L.L.C.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	BUY	$2.02 - $5.04 $24,240 - $60,480	12,000 New	12,000 $25,000
Q4 2022 Feb 07, 2023	BUY	$9.86 - $23.83 $182,912 - $442,070	18,551 New	18,551 $187,000
Q2 2018 Jul 17, 2018	SELL	$9.16 - $13.48 $112,374 - $165,372	-12,268 Closed	0 $0
Q1 2018 Apr 17, 2018	BUY	$6.3 - $13.77 $77,288 - $168,930	12,268 New	12,268 $120,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $235M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.